States must now report how they prevent opioid-treatment drug misuse
H.R. 5630 — To amend the Public Health Service Act to require additional information in State plans for Substance Use Prevention, Treatment, and Recovery Services block grants. · Filed by Erin Houchin (R-IN) · Introduced Sep 30, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires states receiving federal substance-use block grants to provide detailed information about their medication-assisted treatment (MAT) programs—specifically what drugs they use, how they prevent misuse, what misuse data they collect, and what drug-screening protocols they employ. States must report this information as part of their grant applications.
Why we flagged it
The bill is a straightforward amendment to existing grant-administration law that adds transparency and data-collection obligations. It does not create new funding, change eligibility, or alter treatment standards—only what states must report about their existing MAT programs.
What the text implies
- Increased federal data collection on MAT misuse may reveal significant diversion problems in some states, potentially triggering enforcement action or program restructuring.
- States with weak or absent drug-screening protocols will be exposed, creating political pressure to invest in screening infrastructure.
The full analysis lists 3 implications of this text.
Who it affects
The bill increases transparency and accountability in how states manage medication-assisted treatment, a critical tool for opioid addiction. Requiring states to report on drug types, misuse data, and screening protocols enables federal oversight, identifies gaps in diversion prevention, and creates a factual basis for improving treatment quality and safety across states.